Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12727176 | 0.92 | TGFBR1 (0.51) | TGFBR1HDAC1HDAC2GRIA1MAPK14 | |
| SCHEMBL7942534 | 0.89 | MAPK14 (0.50) | TGFBR1GRIA1MAPK14MMP13GPR119 | |
| SCHEMBL15823296 | 0.87 | TGFBR1 (0.58) | TGFBR1HDAC1HDAC2GRIA1USP30 | |
| SCHEMBL1640914 | 0.85 | TGFBR1 (0.46) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| Ammonia Solution, Strong SCHEMBL27870854 | 0.80 | TGFBR1 (0.62) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1640844 | 0.79 | MAPK14 (0.44) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1639802 | 0.79 | MAPK14 (0.66) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1640811 | 0.78 | GPR119 (0.53) | USP30SRCGPR119 | |
| SCHEMBL15824383 | 0.77 | MAPK14 (0.50) | TGFBR1GRIA1MAPK14MMP13BTK | |
| SCHEMBL15830851 | 0.77 | MAPK14 (0.50) | TGFBR1HDAC1HDAC2GRIA1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102686580-B | imidazole derivatives as casein kinase inhibitors | PFIZER | 2014-09-10 | — | — | CN | disclosed |
| EP-2493876-B1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2493876-B1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| CN-102686580-A | Imidazole derivatives as casein kinase inhibitors | PFIZER | 2012-09-19 | — | — | CN | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | CSNK1A1, CSNK1A1L, CSNK1G1 | TGFBR1 3920/4885HDAC1 874/4885HDAC2 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.